Identification

Name
Primaquine
Accession Number
DB01087  (APRD00604)
Type
Small Molecule
Groups
Approved
Description

An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)

Structure
Thumb
Synonyms
  • 6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline
  • 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline
  • 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline
  • Neo-quipenyl
  • Primachin
  • Primachinum
  • Primaquin
  • Primaquina
  • Primaquinum
Product Ingredients
IngredientUNIICASInChI Key
Primaquine phosphateH0982HF78B63-45-6GJOHLWZHWQUKAU-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PrimaquineTablet26.3 mgOralSanofi Aventis1945-12-31Not applicableCanada
Primaquine PhosphateTablet, film coated15 mg/1OralPd Rx Pharmaceuticals, Inc.2010-01-01Not applicableUs
Primaquine PhosphateTablet, film coated15 mg/1Oralbryant ranch prepack2015-04-172017-05-25Us
Primaquine PhosphateTablet, film coated15 mg/1OralSanofi Aventis2011-04-15Not applicableUs
Primaquine PhosphateTablet, film coated15 mg/1OralAvera Mc Kennan Hospital2015-08-24Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Primaquine PhosphateTablet, film coated26.3 mg/1OralAlvogen, Inc.2011-12-08Not applicableUs
Primaquine PhosphateTablet15 mg/1OralAidarex Pharmaceuticals LLC2014-08-012017-09-13Us
Primaquine PhosphateTablet15 mg/1OralLiberty Pharmaceuticals, Inc.2014-08-01Not applicableUs
Primaquine PhosphateTablet15 mg/1OralBayshore Pharmaceuticals, LLC2014-08-01Not applicableUs
Primaquine PhosphateTablet15 mg/1OralAidarex Pharmaceuticals LLC2014-08-01Not applicableUs
Primaquine PhosphateTablet15 mg/1OralGolden State Medical Supply2014-05-08Not applicableUs
Primaquine PhosphateTablet, film coated15 mg/1OralIngenus Pharmaceuticals Nj, Llc2016-06-23Not applicableUs
Primaquine PhosphateTablet15 mg/1OralPd Rx Pharmaceuticals, Inc.2014-08-01Not applicableUs
International/Other Brands
Neo-Quipenyl / Primachin
Categories
UNII
MVR3634GX1
CAS number
90-34-6
Weight
Average: 259.3467
Monoisotopic: 259.168462309
Chemical Formula
C15H21N3O
InChI Key
INDBQLZJXZLFIT-UHFFFAOYSA-N
InChI
InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3
IUPAC Name
N4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine
SMILES
COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1

Pharmacology

Indication

For the treatment of malaria.

Structured Indications
Pharmacodynamics

Primaquine is an antimalarial agent and is the essential co-drug with chloroquine in treating all cases of malaria. In the blood, malaria parasites break down a part of the red blood cells known as haemoglobin. When this happens haemoglobin is divided into two parts; haem and globin. Haem is toxic to the malaria parasite. To prevent it from being damaged, the malaria parasite produces an chemical which converts the toxic haem into a non-toxic product. Primaquine acts by interfering with a part of the parasite (mitochondria) that is responsible for supplying it with energy. Without energy the parasite dies. This stops the infection from continuing and allows the person to recover. Primaquine kills the intrahepatic form of Plasmodium vivax and Plasmodium ovale, and thereby prevents the development of the erythrocytic forms that are responsible for relapses (it also kills gametocytes). Primaquine is not used in the prevention of malaria, only in the treatment. It has insignificant activity against the asexual blood forms of the parasite and therefore it is always used in conjunction with a blood schizonticide and never as a single agent. Primaquine has gametocytocidal activity against all plasmodia, including P. falciparum.

Mechanism of action

Primaquine's mechanism of action is not well understood. It may be acting by generating reactive oxygen species or by interfering with the electron transport in the parasite. Also, although its mechanism of action is unclear, primaquine may bind to and alter the properties of protozoal DNA.

TargetActionsOrganism
AFe(II)-protoporphyrin IX
antagonist
Plasmodium falciparum
UKeratin, type II cytoskeletal 7
other/unknown
Human
URibosyldihydronicotinamide dehydrogenase [quinone]
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

3.7-7.4 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Plasmodium
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
NADH-cytochrome b5 reductase 3---Not AvailableExon 2 c.129C>A / Exon 2 c.149G>A  … show all ADR InferredRisk of methemglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseVilleurbanneNot Available1000_1002delACCADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseTorunNot Available1006A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSunderlandNot Available105_107delCATADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseIwatsukiNot Available1081G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSerresNot Available1082C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseTondelaNot Available1084_1101delCTGAACGAGCGCAAGGCCADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseLoma LindaNot Available1089C->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseAachenNot Available1089C->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseTenriNot Available1096A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseMontpellierNot Available1132G>AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseCalvo MackennaNot Available1138A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseRileyNot Available1139T->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseOlomoucNot Available1141T->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseTomahNot Available1153T->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseLynwoodNot Available1154G->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseMadridNot Available1155C->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseIowa, Walter Reed, SpringfieldNot Available1156A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseBeverly Hills, Genova, Iwate, Niigata, YamaguchiNot Available1160G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseHartfordNot Available1162A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenasePrahaNot Available1166A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseKrakowNot Available1175T>CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseWisconsinNot Available1177C->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseNashville, Anaheim, PorticiNot Available1178G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseAlhambraNot Available1180G->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseBariNot Available1187C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenasePuerto LimonNot Available1192G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseCovao do LoboNot Available1205C>AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseClinicNot Available1215G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseUtrechtNot Available1225C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSuwalkiNot Available1226C->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseRiversideNot Available1228G->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseJapan, ShinagawaNot Available1229G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseKawasakiNot Available1229G->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseMunichNot Available1231A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseGeorgiaNot Available1284C->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSumareNot Available1292T->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseTelti/KobeNot Available1318C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiago de Cuba, MoriokaNot Available1339G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseHarimaNot Available1358T->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseFiguera da FozNot Available1366G->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseAmiensNot Available1367A>TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkok NoiNot Available1376G->T, 1502T->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseFukayaNot Available1462G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseCampinasNot Available1463G->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseBuenos AiresNot Available1465C>TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseArakawaNot Available1466C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseBrightonNot Available1488_1490delGAAADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseKozukataNot Available159G->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseAmsterdamNot Available180_182delTCTADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseNo nameNot Available202G->A, 376A->G, 1264C>GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSwanseaNot Available224T->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseUrayasuNot Available281_283delAGAADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseVancouverNot Available317C->G544C->T592C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseMt SinaiNot Available376A->G, 1159C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenasePlymouthNot Available488G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseVolendamNot Available514C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseShinshuNot Available527A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseChikugoNot Available535A->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseTsukuiNot Available561_563delCTCADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenasePedoplis-CkaroNot Available573C>GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiagoNot Available593G->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseMinnesota, Marion, Gastonia, LeJeuneNot Available637G->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseCincinnatiNot Available637G->T, 1037A->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseHarilaouNot Available648T->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseNorth DallasNot Available683_685delACAADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahikawaNot Available695G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseDurhamNot Available713A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseStonybrookNot Available724_729delGGCACTADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseWayneNot Available769C->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseAveiroNot Available806G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseCleveland CorumNot Available820G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseLilleNot Available821A>TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkokNot Available825G>CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSugaoNot Available826C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseLa JollaNot Available832T->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseWexhamNot Available833C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenasePiotrkowNot Available851T>CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseWest VirginiaNot Available910G->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseOmiyaNot Available921G->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseNaraNot Available953_976delCCACCAAAGGGTACCTGGAC GACCADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseManhattanNot Available962G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseRehevotNot Available964T->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseHoniaraNot Available99A->G / 1360C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseTokyo, FukushimaNot Available1246G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseChathamNot Available1003G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseFushanNot Available1004C->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenasePartenopeNot Available1052G->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseIerapetraNot Available1057C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseAnadiaNot Available1193A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseAbenoNot Available1220A->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSurabayaNot Available1291G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenasePawneeNot Available1316G->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseS. AntiocoNot Available1342A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseCassanoNot Available1347G->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseHermoupolisNot Available1347G->C / 1360C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseUnion,Maewo, Chinese-2, KaloNot Available1360C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseAndalusNot Available1361G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseCosenzaNot Available1376G->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseCanton, Taiwan- Hakka, Gifu-like, Agrigento-likeNot Available1376G->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseFloresNot Available1387C->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseKaiping, Anant, Dhon, Sapporo-like, WoseraNot Available1388G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseKamogawaNot Available169C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseCostanzoNot Available179T>CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseAmazoniaNot Available185C->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSongklanagarindNot Available196T->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseHechiNot Available202G->A / 871G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseNamouruNot Available208T->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseBao LocNot Available352T>CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseCrispimNot Available375G->T, 379G->T383T->C384C>TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseAcrokorinthosNot Available376A->G / 463C->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSanta MariaNot Available376A->G / 542A->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseAnanindeuaNot Available376A->G / 871G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseVanua LavaNot Available383T->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseValladolidNot Available406C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseBelemNot Available409C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseLiuzhouNot Available442G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseShenzenNot Available473G>AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseTaipei “Chinese- 3”Not Available493A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseToledoNot Available496C>TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseNaoneNot Available497G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseNankangNot Available517T->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseMiaoliNot Available519C->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseMediterranean, Dallas, Panama‚ Sassari, Cagliari, BirminghamNot Available563C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseCoimbra ShundeNot Available592C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseNilgiriNot Available593G>AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseRadlowoNot Available679C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseRoubaixNot Available811G>CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseHaikouNot Available835A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-1Not Available835A->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseMizushimaNot Available848A>GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseOsakaNot Available853C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseViangchan, JammuNot Available871G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSeoulNot Available916G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseLudhianaNot Available929G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseFarroupilhaNot Available977C->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-5Not Available1024C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseRignanoNot Available130G>AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseOrissaNot Available131C->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseG6PDNiceNot Available1380G>CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseKamiube, KeelungNot Available1387C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseNeapolisNot Available1400C->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseAuresNot Available143T->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSplitNot Available1442C->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseKambosNot Available148C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenasePalestrinaNot Available170G>AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseMetapontoNot Available172G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseMusashinoNot Available185C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahiNot Available202G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (202), Ferrara INot Available202G->A / 376A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseMurcia OristanoNot Available209A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseUbe KonanNot Available241C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseLagosantoNot Available242G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseGuangzhouNot Available274C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseHammersmithNot Available323T->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSinnaiNot Available34G->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (680)Not Available376A->G / 680G->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (968), Betica,Selma, GuantanamoNot Available376A->G / 968T->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSalerno PyrgosNot Available383T>GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseQuing YanNot Available392G->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseLagesNot Available40G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseIleshaNot Available466G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseMahidolNot Available487G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseMalagaNot Available542A->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSibariNot Available634A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseMexico CityNot Available680G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseNanningNot Available703C->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseSeattle, Lodi, Modena, Ferrara II, Athens-likeNot Available844G->CADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseBajo MaumereNot Available844G->TADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseMontalbanoNot Available854G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseKalyan-Kerala, Jamnaga, RohiniNot Available949G->AADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details
Glucose-6-phosphate 1-dehydrogenaseGaoheNot Available95A->GADR InferredIncreased risk of potentially fatal hemolysis. Associated with leukopenia.Details

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Primaquine can be increased when it is combined with Abiraterone.Approved
AcebutololThe metabolism of Acebutolol can be decreased when combined with Primaquine.Approved
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Primaquine.Approved, Vet Approved
AceprometazineThe serum concentration of Aceprometazine can be increased when it is combined with Primaquine.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Primaquine.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be increased when it is combined with Primaquine.Experimental
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Primaquine.Approved, Vet Approved
Albendazole oxideThe serum concentration of Albendazole oxide can be decreased when it is combined with Primaquine.Experimental
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Primaquine.Approved, Vet Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Primaquine.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Primaquine.Approved
AmiodaroneThe metabolism of Primaquine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Primaquine.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Primaquine.Approved
AnagrelidePrimaquine may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
AprepitantThe serum concentration of Primaquine can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
ArotinololThe metabolism of Arotinolol can be decreased when combined with Primaquine.Approved, Investigational
ArsenamideThe serum concentration of Arsenamide can be decreased when it is combined with Primaquine.Vet Approved
Arsenic trioxidePrimaquine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Primaquine.Approved
ArtemotilThe serum concentration of Artemotil can be decreased when it is combined with Primaquine.Experimental
AsenapinePrimaquine may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe metabolism of Primaquine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe metabolism of Atenolol can be decreased when combined with Primaquine.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Primaquine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Primaquine is combined with Atorvastatin.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Primaquine.Approved
BedaquilinePrimaquine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololThe metabolism of Befunolol can be decreased when combined with Primaquine.Experimental
BenzimidazoleThe serum concentration of Benzimidazole can be decreased when it is combined with Primaquine.Experimental, Investigational
BepheniumThe serum concentration of Bephenium can be decreased when it is combined with Primaquine.Experimental
BetaxololThe metabolism of Betaxolol can be decreased when combined with Primaquine.Approved
BevantololThe metabolism of Bevantolol can be decreased when combined with Primaquine.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Primaquine.Approved
BithionolThe serum concentration of Bithionol can be decreased when it is combined with Primaquine.Withdrawn
BL-1020The serum concentration of BL-1020 can be increased when it is combined with Primaquine.Investigational
BoceprevirThe metabolism of Primaquine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololThe metabolism of Bopindolol can be decreased when combined with Primaquine.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
BosentanThe serum concentration of Primaquine can be decreased when it is combined with Bosentan.Approved, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Primaquine.Approved, Investigational
BucindololThe metabolism of Bucindolol can be decreased when combined with Primaquine.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Primaquine.Experimental, Investigational
BunamidineThe serum concentration of Bunamidine can be decreased when it is combined with Primaquine.Vet Approved
BupranololThe metabolism of Bupranolol can be decreased when combined with Primaquine.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Primaquine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Primaquine.Approved
CaffeineThe metabolism of Primaquine can be decreased when combined with Caffeine.Approved
CambendazoleThe serum concentration of Cambendazole can be decreased when it is combined with Primaquine.Vet Approved
CarbamazepineThe metabolism of Primaquine can be increased when combined with Carbamazepine.Approved, Investigational
CarbendazimThe serum concentration of Carbendazim can be decreased when it is combined with Primaquine.Investigational
CarteololThe metabolism of Carteolol can be decreased when combined with Primaquine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Primaquine.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Primaquine.Approved, Investigational
CeritinibThe serum concentration of Primaquine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Primaquine.Withdrawn
ChloroquineChloroquine may increase the QTc-prolonging activities of Primaquine.Approved, Vet Approved
ChloroxylenolThe serum concentration of Chloroxylenol can be decreased when it is combined with Primaquine.Approved
ChlorproethazineThe serum concentration of Chlorproethazine can be increased when it is combined with Primaquine.Experimental
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Primaquine.Approved, Vet Approved
CiclobendazoleThe serum concentration of Ciclobendazole can be decreased when it is combined with Primaquine.Experimental
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
CisapridePrimaquine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Primaquine can be decreased when combined with Citalopram.Approved
ClarithromycinPrimaquine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Primaquine can be decreased when combined with Clemastine.Approved
ClomipramineClomipramine may increase the QTc-prolonging activities of Primaquine.Approved, Vet Approved
CloranololThe metabolism of Cloranolol can be decreased when combined with Primaquine.Experimental
ClorsulonThe serum concentration of Clorsulon can be decreased when it is combined with Primaquine.Vet Approved
ClotrimazoleThe metabolism of Primaquine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Primaquine.Approved
CobicistatThe metabolism of Primaquine can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Primaquine can be increased when it is combined with Conivaptan.Approved, Investigational
CoumaphosThe serum concentration of Coumaphos can be decreased when it is combined with Primaquine.Vet Approved
CrizotinibPrimaquine may increase the QTc-prolonging activities of Crizotinib.Approved
CyclosporineThe metabolism of Primaquine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be increased when it is combined with Primaquine.Experimental
Cyproterone acetateThe serum concentration of Primaquine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Primaquine can be decreased when it is combined with Dabrafenib.Approved
DapsoneThe risk or severity of adverse effects can be increased when Primaquine is combined with Dapsone.Approved, Investigational
DarunavirThe metabolism of Primaquine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Primaquine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Primaquine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Primaquine.Approved
DelavirdineThe metabolism of Primaquine can be decreased when combined with Delavirdine.Approved
DesaspidinThe serum concentration of Desaspidin can be decreased when it is combined with Primaquine.Experimental
DesfluraneDesflurane may increase the QTc-prolonging activities of Primaquine.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Primaquine.Approved
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Primaquine.Approved
DichloropheneThe serum concentration of Dichlorophene can be decreased when it is combined with Primaquine.Vet Approved
DichlorvosThe serum concentration of Dichlorvos can be decreased when it is combined with Primaquine.Vet Approved
DiethylcarbamazineThe serum concentration of Diethylcarbamazine can be decreased when it is combined with Primaquine.Approved, Investigational, Vet Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Primaquine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Primaquine.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Primaquine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Primaquine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Primaquine.Experimental
DihydroergotamineThe metabolism of Primaquine can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Primaquine can be decreased when combined with Diltiazem.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Primaquine.Approved
DisopyramidePrimaquine may increase the QTc-prolonging activities of Disopyramide.Approved
DithiazanineThe serum concentration of Dithiazanine can be decreased when it is combined with Primaquine.Vet Approved
DofetilidePrimaquine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Primaquine.Approved
DomperidonePrimaquine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe serum concentration of Doramectin can be decreased when it is combined with Primaquine.Vet Approved
DosulepinThe metabolism of Primaquine can be decreased when combined with Dosulepin.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Primaquine.Approved
DoxycyclineThe metabolism of Primaquine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Primaquine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Primaquine.Approved, Vet Approved
EliglustatPrimaquine may increase the QTc-prolonging activities of Eliglustat.Approved
EmetineThe serum concentration of Emetine can be decreased when it is combined with Primaquine.Experimental
EnzalutamideThe serum concentration of Primaquine can be decreased when it is combined with Enzalutamide.Approved
EpanololThe metabolism of Epanolol can be decreased when combined with Primaquine.Experimental
EprinomectinThe serum concentration of Eprinomectin can be decreased when it is combined with Primaquine.Vet Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Primaquine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Primaquine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Primaquine.Approved, Vet Approved
EscitalopramPrimaquine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmololThe metabolism of Esmolol can be decreased when combined with Primaquine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Primaquine.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Primaquine.Approved
FebantelThe serum concentration of Febantel can be decreased when it is combined with Primaquine.Vet Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Primaquine.Approved
FenbendazoleThe serum concentration of Fenbendazole can be decreased when it is combined with Primaquine.Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Primaquine.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
FlecainidePrimaquine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlubendazoleThe serum concentration of Flubendazole can be decreased when it is combined with Primaquine.Approved, Withdrawn
FluconazoleFluconazole may increase the QTc-prolonging activities of Primaquine.Approved
FluoxetinePrimaquine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolPrimaquine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Primaquine.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Primaquine.Approved
FluvoxamineThe metabolism of Primaquine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
FosamprenavirThe metabolism of Primaquine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Primaquine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Primaquine.Approved
FosphenytoinThe metabolism of Primaquine can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Primaquine can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Primaquine.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Primaquine.Approved
GemifloxacinPrimaquine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GitoformateThe serum concentration of Gitoformate can be increased when it is combined with Primaquine.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Primaquine.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
HaloperidolHaloperidol may increase the QTc-prolonging activities of Primaquine.Approved
HexylresorcinolThe serum concentration of Hexylresorcinol can be decreased when it is combined with Primaquine.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Primaquine.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Primaquine.Approved
Hygromycin BThe serum concentration of Hygromycin B can be decreased when it is combined with Primaquine.Vet Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
IbutilidePrimaquine may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Primaquine can be increased when it is combined with Idelalisib.Approved
IloperidonePrimaquine may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Primaquine can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Primaquine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Primaquine.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Primaquine.Approved
IndenololThe metabolism of Indenolol can be decreased when combined with Primaquine.Withdrawn
IndinavirThe metabolism of Primaquine can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Primaquine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Primaquine.Approved, Vet Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Primaquine.Approved
ItraconazoleThe metabolism of Primaquine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Primaquine.Approved
IvacaftorThe serum concentration of Primaquine can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Primaquine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Primaquine.Approved
Lanatoside CThe serum concentration of Lanatoside C can be increased when it is combined with Primaquine.Experimental
LandiololThe metabolism of Landiolol can be decreased when combined with Primaquine.Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
LenvatinibPrimaquine may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
LevamisoleThe serum concentration of Levamisole can be decreased when it is combined with Primaquine.Investigational, Vet Approved, Withdrawn
LevobunololThe metabolism of Levobunolol can be decreased when combined with Primaquine.Approved
LevofloxacinPrimaquine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LidocaineThe metabolism of Primaquine can be decreased when combined with Lidocaine.Approved, Vet Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Primaquine.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Primaquine.Approved
LobeglitazoneThe metabolism of Primaquine can be decreased when combined with Lobeglitazone.Approved, Investigational
LopinavirThe metabolism of Primaquine can be decreased when combined with Lopinavir.Approved
LovastatinThe metabolism of Primaquine can be decreased when combined with Lovastatin.Approved, Investigational
LucanthoneThe serum concentration of Lucanthone can be decreased when it is combined with Primaquine.Approved, Investigational
LuliconazoleThe serum concentration of Primaquine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Primaquine can be increased when combined with Lumacaftor.Approved
LumefantrineThe risk or severity of adverse effects can be increased when Primaquine is combined with Lumefantrine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Primaquine.Illicit, Investigational, Withdrawn
MaprotilineMaprotiline may increase the QTc-prolonging activities of Primaquine.Approved
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Primaquine.Approved, Vet Approved
MefloquineThe risk or severity of adverse effects can be increased when Primaquine is combined with Mefloquine.Approved
MepindololThe metabolism of Mepindolol can be decreased when combined with Primaquine.Experimental
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Primaquine.Approved, Investigational
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Primaquine.Experimental
MethadoneMethadone may increase the QTc-prolonging activities of Primaquine.Approved
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Primaquine.Approved
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Primaquine.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Primaquine.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Primaquine.Approved
MetildigoxinThe serum concentration of Metildigoxin can be increased when it is combined with Primaquine.Experimental
MetipranololThe metabolism of Metipranolol can be decreased when combined with Primaquine.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Primaquine.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Primaquine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Primaquine.Experimental
MexiletineThe metabolism of Primaquine can be decreased when combined with Mexiletine.Approved
MidostaurinThe metabolism of Primaquine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Primaquine can be increased when it is combined with Mifepristone.Approved, Investigational
Milbemycin oximeThe serum concentration of Milbemycin oxime can be decreased when it is combined with Primaquine.Vet Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Primaquine.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Primaquine.Approved
MitotaneThe serum concentration of Primaquine can be decreased when it is combined with Mitotane.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Primaquine.Approved
MorantelThe serum concentration of Morantel can be decreased when it is combined with Primaquine.Vet Approved
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Primaquine.Approved, Investigational, Withdrawn
MoxidectinThe serum concentration of Moxidectin can be decreased when it is combined with Primaquine.Vet Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
NadololThe metabolism of Nadolol can be decreased when combined with Primaquine.Approved
NefazodoneThe metabolism of Primaquine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Primaquine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Primaquine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Primaquine can be increased when combined with Nevirapine.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Primaquine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Primaquine.Approved, Investigational
NiclosamideThe serum concentration of Niclosamide can be decreased when it is combined with Primaquine.Approved, Investigational, Vet Approved
NilotinibThe metabolism of Primaquine can be decreased when combined with Nilotinib.Approved, Investigational
NiridazoleThe serum concentration of Niridazole can be decreased when it is combined with Primaquine.Experimental
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Primaquine.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Primaquine.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Primaquine.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
OfloxacinPrimaquine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
OlaparibThe metabolism of Primaquine can be decreased when combined with Olaparib.Approved
OleandrinThe serum concentration of Oleandrin can be increased when it is combined with Primaquine.Experimental
OlodaterolOlodaterol may increase the QTc-prolonging activities of Primaquine.Approved
OltiprazThe serum concentration of Oltipraz can be decreased when it is combined with Primaquine.Investigational
OndansetronOndansetron may increase the QTc-prolonging activities of Primaquine.Approved
OsimertinibThe serum concentration of Primaquine can be increased when it is combined with Osimertinib.Approved
OuabainThe serum concentration of Ouabain can be increased when it is combined with Primaquine.Approved
OxamniquineThe serum concentration of Oxamniquine can be decreased when it is combined with Primaquine.Approved
OxantelThe serum concentration of Oxantel can be decreased when it is combined with Primaquine.Experimental
OxfendazoleThe serum concentration of Oxfendazole can be decreased when it is combined with Primaquine.Vet Approved
OxibendazoleThe serum concentration of Oxibendazole can be decreased when it is combined with Primaquine.Investigational, Vet Approved
OxprenololThe metabolism of Oxprenolol can be decreased when combined with Primaquine.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Primaquine.Approved, Vet Approved
PalbociclibThe serum concentration of Primaquine can be increased when it is combined with Palbociclib.Approved
PaliperidonePrimaquine may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatPrimaquine may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParoxetineParoxetine may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Primaquine.Approved
PazopanibPrimaquine may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Primaquine can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe metabolism of Penbutolol can be decreased when combined with Primaquine.Approved, Investigational
PentamidinePentamidine may increase the QTc-prolonging activities of Primaquine.Approved
PentobarbitalThe metabolism of Primaquine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerazineThe serum concentration of Perazine can be increased when it is combined with Primaquine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Primaquine.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Primaquine.Approved, Investigational, Vet Approved, Withdrawn
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Primaquine.Approved
PeruvosideThe serum concentration of Peruvoside can be increased when it is combined with Primaquine.Experimental
PhenobarbitalThe metabolism of Primaquine can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Primaquine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozidePrimaquine may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Primaquine.Approved
PiperazineThe serum concentration of Piperazine can be decreased when it is combined with Primaquine.Approved, Vet Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Primaquine.Approved
PosaconazoleThe metabolism of Primaquine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe metabolism of Practolol can be decreased when combined with Primaquine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Primaquine.Approved
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Primaquine.Approved, Vet Approved
PrilocaineThe risk or severity of adverse effects can be increased when Primaquine is combined with Prilocaine.Approved
PrimidoneThe metabolism of Primaquine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamidePrimaquine may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Primaquine.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Primaquine.Approved, Vet Approved
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Primaquine.Approved
PropafenonePrimaquine may increase the QTc-prolonging activities of Propafenone.Approved
PropiopromazineThe serum concentration of Propiopromazine can be increased when it is combined with Primaquine.Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Primaquine.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Primaquine.Approved, Investigational
ProscillaridinThe serum concentration of Proscillaridin can be increased when it is combined with Primaquine.Experimental
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Primaquine.Approved
PyrantelThe serum concentration of Pyrantel can be decreased when it is combined with Primaquine.Approved, Vet Approved
PyrviniumThe serum concentration of Pyrvinium can be decreased when it is combined with Primaquine.Approved
QuetiapinePrimaquine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Primaquine.Approved, Investigational
QuinidinePrimaquine may increase the QTc-prolonging activities of Quinidine.Approved
QuininePrimaquine may increase the QTc-prolonging activities of Quinine.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
RifabutinThe metabolism of Primaquine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Primaquine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Primaquine can be increased when combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Primaquine.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
RitonavirThe metabolism of Primaquine can be decreased when combined with Ritonavir.Approved, Investigational
RopiniroleThe metabolism of Primaquine can be decreased when combined with Ropinirole.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Primaquine.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Primaquine.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Primaquine.Approved
SaquinavirPrimaquine may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SertralineSertraline may increase the QTc-prolonging activities of Primaquine.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Primaquine.Approved, Vet Approved
SildenafilThe metabolism of Primaquine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Primaquine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Primaquine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Primaquine.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Primaquine is combined with Sodium Nitrite.Approved
Sodium stibogluconateThe serum concentration of Sodium stibogluconate can be decreased when it is combined with Primaquine.Approved, Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Primaquine.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
SotalolThe metabolism of Sotalol can be decreased when combined with Primaquine.Approved
St. John's WortThe serum concentration of Primaquine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StibophenThe serum concentration of Stibophen can be decreased when it is combined with Primaquine.Experimental
StiripentolThe serum concentration of Primaquine can be increased when it is combined with Stiripentol.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Primaquine.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Primaquine.Approved, Vet Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
SuraminThe serum concentration of Suramin can be decreased when it is combined with Primaquine.Approved, Investigational
TalinololThe metabolism of Talinolol can be decreased when combined with Primaquine.Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Primaquine.Approved
TelaprevirThe metabolism of Primaquine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinPrimaquine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Primaquine.Approved
Tenofovir disoproxilThe metabolism of Primaquine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbutalineTerbutaline may increase the QTc-prolonging activities of Primaquine.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Primaquine.Experimental
TeriflunomideThe serum concentration of Primaquine can be decreased when it is combined with Teriflunomide.Approved
TertatololThe metabolism of Tertatolol can be decreased when combined with Primaquine.Experimental
TetrabenazinePrimaquine may increase the QTc-prolonging activities of Tetrabenazine.Approved
TheophyllineThe metabolism of Primaquine can be decreased when combined with Theophylline.Approved
ThiabendazoleThe serum concentration of Thiabendazole can be decreased when it is combined with Primaquine.Approved, Vet Approved
ThiazinamThe serum concentration of Thiazinam can be increased when it is combined with Primaquine.Experimental
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Primaquine.Withdrawn
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Primaquine.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Primaquine.Approved
TiclopidineThe metabolism of Primaquine can be decreased when combined with Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Primaquine.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Primaquine.Approved
TocilizumabThe serum concentration of Primaquine can be decreased when it is combined with Tocilizumab.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
ToremifenePrimaquine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
TrichlorfonThe serum concentration of Trichlorfon can be decreased when it is combined with Primaquine.Vet Approved
TriclabendazoleThe serum concentration of Triclabendazole can be decreased when it is combined with Primaquine.Investigational
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Primaquine.Approved
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Primaquine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Primaquine.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Primaquine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Primaquine.Approved, Vet Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Primaquine.Approved, Experimental
VandetanibPrimaquine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Primaquine.Approved
VemurafenibThe serum concentration of Primaquine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Primaquine.Approved
VerapamilThe metabolism of Primaquine can be decreased when combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Primaquine.Approved
VoriconazoleThe metabolism of Primaquine can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Primaquine.Approved, Investigational
ZiprasidoneThe metabolism of Primaquine can be decreased when combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Primaquine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolPrimaquine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take with food to decrease dyspepsia.

References

General References
  1. Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Breckenridge AM: Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol. 1985 Jun;19(6):745-50. [PubMed:4027117]
  2. ALVING AS, ARNOLD J, HOCKWALD RS, CLAYMAN CB, DERN RJ, BEUTLER E, FLANAGAN CL: Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med. 1955 Aug;46(2):301-6. [PubMed:13242948]
  3. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ: Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006 Sep;75(3):402-15. [PubMed:16968913]
  4. Cohen RJ, Sachs JR, Wicker DJ, Conrad ME: Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam. N Engl J Med. 1968 Nov 21;279(21):1127-31. [PubMed:5686480]
  5. Coleman MD, Coleman NA: Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf. 1996 Jun;14(6):394-405. [PubMed:8828017]
External Links
Human Metabolome Database
HMDB15219
KEGG Compound
C07627
PubChem Compound
4908
PubChem Substance
46508222
ChemSpider
4739
BindingDB
71542
ChEBI
8405
ChEMBL
CHEMBL506
Therapeutic Targets Database
DAP000216
PharmGKB
PA451103
Drugs.com
Drugs.com Drug Page
Wikipedia
Primaquine
ATC Codes
P01BA03 — Primaquine
AHFS Codes
  • 08:30.08 — Antimalarials
FDA label
Download (105 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableObese1
1CompletedBasic SciencePlasmodium Infections1
1CompletedPreventionPlasmodium Infections1
1CompletedTreatmentG6PD Deficient / G6PD Normal / Healthy Volunteers1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentMalaria caused by plasmodium vivax1
1RecruitingBasic SciencePlasmodium Infections1
1RecruitingHealth Services ResearchPharmacologic Actions1
1, 2CompletedTreatmentPlasmodium Infections2
1, 2RecruitingTreatmentDrug Combination / Healthy Volunteers / Pharmacokinetics1
2CompletedTreatmentMalaria caused by Plasmodium falciparum1
2CompletedTreatmentMalaria caused by plasmodium vivax1
2CompletedTreatmentPlasmodium Infections2
2CompletedTreatmentPlasmodium Infections / Plasmodium Vivax1
2CompletedTreatmentUncomplicated Falciparum Malaria1
2Not Yet RecruitingTreatmentMalaria caused by plasmodium vivax1
2, 3CompletedTreatmentMalaria caused by plasmodium vivax1
3CompletedPreventionMalaria caused by Plasmodium falciparum1
3CompletedTreatmentAsymptomatic Malaria / Plasmodium Falciparum / Plasmodium Infections1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii1
3CompletedTreatmentMalaria caused by Plasmodium falciparum / Malaria caused by plasmodium vivax / Plasmodium Infections1
3CompletedTreatmentMalaria caused by plasmodium vivax3
3CompletedTreatmentMalaria caused by plasmodium vivax / Plasmodium Infections1
3CompletedTreatmentPlasmodium Infections1
3CompletedTreatmentUncomplicated Plasmodium Knowlesi Malaria1
3Not Yet RecruitingTreatmentMalaria caused by plasmodium vivax1
3RecruitingTreatmentPlasmodium Vivax Malaria Without Complication1
4CompletedBasic SciencePlasmodium Falciparum Clinical Episode / Plasmodium Falciparum Infection / Plasmodium Vivax Clinical Episode / Plasmodium Vivax Infection1
4CompletedPreventionPlasmodium Falciparum1
4CompletedPreventionPlasmodium Infections1
4CompletedTreatmentGlucose-6-Phosphate Dehydrogenase Deficiency / Malaria caused by Plasmodium falciparum1
4CompletedTreatmentPlasmodium Infections3
4CompletedTreatmentPlasmodium Vivax Infection1
4RecruitingPreventionParasitic Diseases / Plasmodium Infections1
4RecruitingTreatmentMalaria caused by Plasmodium falciparum1
4RecruitingTreatmentPlasmodium Vivax1
4Unknown StatusTreatmentMalaria caused by plasmodium vivax1
4WithdrawnTreatmentPneumonia, Pneumocystis Carinii1
Not AvailableCompletedNot AvailableMalaria caused by plasmodium vivax1
Not AvailableCompletedPreventionFavism / Glucosephosphate Dehydrogenase Deficiency1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii1
Not AvailableCompletedTreatmentPlasmodium Infections1
Not AvailableRecruitingTreatmentUncomplicated Vivax Malaria1
Not AvailableSuspendedTreatmentUncomplicated Plasmodium Falciparum Malaria1
Not AvailableUnknown StatusNot AvailableParasitemia1
Not AvailableUnknown StatusPreventionMalaria caused by plasmodium vivax1
Not AvailableUnknown StatusTreatmentPlasmodium Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral26.3 mg
TabletOral15 mg/1
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral26.3 mg/1
Prices
Unit descriptionCostUnit
Primaquin phosphate powder18.2USD g
Primaquine 26.3 mg tablet1.51USD tablet
Primaquine Phosphate 15 mg Tablet0.43USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
boiling point (°C)177 °C at 2.00E-01 mm HgPhysProp
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0564 mg/mLALOGPS
logP2.76ALOGPS
logP1.64ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)17.11ChemAxon
pKa (Strongest Basic)10.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area60.17 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity78.51 m3·mol-1ChemAxon
Polarizability29.92 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9776
Blood Brain Barrier+0.9787
Caco-2 permeable-0.5622
P-glycoprotein substrateSubstrate0.8018
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.7681
Renal organic cation transporterInhibitor0.5501
CYP450 2C9 substrateNon-substrate0.8703
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5723
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.93
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5057
Ames testAMES toxic0.9106
CarcinogenicityNon-carcinogens0.9283
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4474 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7858
hERG inhibition (predictor II)Inhibitor0.8162
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01p6-4290000000-d5f33ea098bbcd333ccf
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000l-9360000000-9f32d7ddbda48f0e2dc5
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-002r-9530000000-5c70a8800c55df1915e7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-002r-9810000000-89e3b0e2b3cb4d1e9293
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00n0-5900000000-cbe196964f610f8bf1ff
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00o9-3900000000-6209d7be74ea608e7fc2
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0190000000-32ab0ba382901a73b1c0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-002f-1690000000-82416f4c3f338eece150
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0920000000-65f7b4135f0db6eee15e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0900000000-17b7474db1209213f689
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0900000000-b2c7e131a6a25d115853
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01r6-0970000000-a3b1021cda642a6141b8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-2900000000-d3dfd1b72d458ffd07d7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01p6-4290000000-314f515d08e6730a1df9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000l-9360000000-3933ab4d9c2c3918ecce
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-002r-9530000000-65625d68f98ae8f36ea0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-002r-7910000000-6c3e274b81107c5e98eb

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminoquinolines and derivatives. These are organic compounds containing an amino group attached to a quinoline ring system.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Aminoquinolines and derivatives
Direct Parent
Aminoquinolines and derivatives
Alternative Parents
Methoxyanilines / Anisoles / Secondary alkylarylamines / Alkyl aryl ethers / Pyridines and derivatives / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives
Substituents
Aminoquinoline / Methoxyaniline / Anisole / Alkyl aryl ether / Secondary aliphatic/aromatic amine / Pyridine / Benzenoid / Heteroaromatic compound / Ether / Azacycle
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
aromatic ether, N-substituted diamine, aminoquinoline (CHEBI:8405)

Targets

1. Fe(II)-protoporphyrin IX
Kind
Small molecule
Organism
Plasmodium falciparum
Pharmacological action
Yes
Actions
Antagonist
References
  1. Dorn A, Vippagunta SR, Matile H, Jaquet C, Vennerstrom JL, Ridley RG: An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochem Pharmacol. 1998 Mar 15;55(6):727-36. [PubMed:9586944]
  2. Fitch CD: Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci. 2004 Mar 5;74(16):1957-72. [PubMed:14967191]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Structural molecule activity
Specific Function
Blocks interferon-dependent interphase and stimulates DNA synthesis in cells. Involved in the translational regulation of the human papillomavirus type 16 E7 mRNA (HPV16 E7).
Gene Name
KRT7
Uniprot ID
P08729
Uniprot Name
Keratin, type II cytoskeletal 7
Molecular Weight
51385.11 Da
References
  1. Heard CM, Monk BV, Modley AJ: Binding of primaquine to epidermal membranes and keratin. Int J Pharm. 2003 May 12;257(1-2):237-44. [PubMed:12711178]
  2. Basso LG, Rodrigues RZ, Naal RM, Costa-Filho AJ: Effects of the antimalarial drug primaquine on the dynamic structure of lipid model membranes. Biochim Biophys Acta. 2011 Jan;1808(1):55-64. doi: 10.1016/j.bbamem.2010.08.009. Epub 2010 Aug 14. [PubMed:20713019]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Nadph dehydrogenase (quinone) activity
Specific Function
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vi...
Gene Name
NQO2
Uniprot ID
P16083
Uniprot Name
Ribosyldihydronicotinamide dehydrogenase [quinone]
Molecular Weight
25918.4 Da
References
  1. Graves PR, Kwiek JJ, Fadden P, Ray R, Hardeman K, Coley AM, Foley M, Haystead TA: Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol Pharmacol. 2002 Dec;62(6):1364-72. [PubMed:12435804]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49